Summary & Overview
CPT 0534U: PROSTOX™ ultra - Genitourinary Toxicity Risk Score
CPT code 0534U designates PROSTOX™ ultra, a Proprietary Laboratory Analyses (PLA) test by MiraDx Inc. that evaluates 32 genetic markers (microRNAs and SNPs) via RT–PCR to produce a risk score for genitourinary toxicity after radiation therapy. The code is significant nationally as precision oncology and personalized toxicity risk profiling influence treatment planning and shared decision-making for patients undergoing prostate-directed radiation.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test’s clinical purpose, typical service and site-of-service settings, and the policy and reimbursement context relevant to proprietary lab tests. The publication summarizes payer coverage trends, coding and billing considerations for PLA codes, and clinical context on how a molecular risk score may be used to inform radiation planning.
The report is designed to inform billing and compliance professionals, laboratory administrators, and clinicians about the role of CPT code 0534U in documenting PROSTOX™ ultra testing, expected sites of service, and where to look for payer-specific policy details. Data not available in the input will be noted as such in the detailed sections.
Billing Code Overview
CPT code 0534U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the PROSTOX™ ultra test from MiraDx Inc. The test analyzes 32 genetic variants, including microRNAs and single–nucleotide polymorphisms (SNPs), using reverse transcription polymerase chain reaction (RT–PCR) and generates a risk score that estimates the likelihood of genitourinary toxicity following radiation therapy.
Service type: Proprietary laboratory genetic risk assessment using RT–PCR
Typical site of service: Clinical laboratory or contracted specialty lab; specimen collection in outpatient clinic or hospital outpatient setting
Clinical & Coding Specifications
Clinical Context
A 68-year-old man with localized prostate adenocarcinoma is scheduled to receive external beam radiation therapy. The radiation oncology team orders the PROSTOX™ ultra test (0534U) from MiraDx Inc. prior to treatment planning to assess the patient’s genetic risk of developing genitourinary (GU) toxicity after radiation. A peripheral blood sample is collected in the outpatient oncology clinic or hospital laboratory and sent to the manufacturer’s laboratory. The lab performs reverse transcription polymerase chain reaction (RT–PCR) to analyze 32 genetic variants, including microRNAs and single–nucleotide polymorphisms (SNPs). The test returns a risk score indicating low, intermediate, or high likelihood of post-radiation GU toxicity. The treating radiation oncologist reviews the result during treatment planning to inform dose constraints, fractionation decisions, and discussion of anticipated side effects with the patient. Typical sites of service for ordering, sample collection, and care coordination include outpatient radiation oncology clinics, hospital outpatient departments, and clinical laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity for specimen collection or documentation is substantially greater than typical for this test and supporting documentation is appended. |
52 | Reduced services | Use when the test was partially reduced or not completed as planned (for example, inadequate sample that allowed only partial analysis) and documentation supports the reduction. |
53 | Discontinued procedure | Use when testing is started but discontinued due to patient factors or specimen issues before completion; document reason for discontinuation. |
59 | Distinct procedural service | Use when reporting another distinct service on the same day that is unrelated to the PLA test and needs separation (use cautiously and per payer rules). |
76 | Repeat procedure by same provider | Use when the same PLA test is repeated by the same laboratory because of initial analytic failure and full repeat testing is performed. |
77 | Repeat procedure by another provider | Use when the test is repeated by a different laboratory following an inadequate or invalid result from the initial lab. |
90 | Reference (outside) laboratory | Use when the performing laboratory bills the test as performed by an outside/reference laboratory; indicates referral testing arrangements. |
91 | Repeat clinical diagnostic laboratory test | Use when the identical laboratory test is repeated on the same day to confirm an unexpected result. |
TC | Technical component | Use when billing only the technical component of the test (laboratory processing) separate from professional interpretation, if payer allows component billing for PLA tests. |
26 | Professional component | Use when billing only the professional component (interpretation/reporting) separate from the lab technical processing, if applicable. |
PR | Payer-specific reporting | Use when required by a specific payer for reporting purposes (apply only where a payer requires this modifier). |
GA | Waiver of liability statement on file | Use when the patient has signed an Advance Beneficiary Notice or equivalent and the provider expects noncoverage. |
JW | Drug discarded/not administered (if applicable) | Rarely applicable; use only if a specimen-related reagent or kit component is billed and discarded — document per payer policy. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RC0000X | Radiation Oncology | Radiation oncologists order the test to inform radiation planning and toxicity risk assessment. |
| 207L00000X | Medical Oncology | Medical oncologists may order or review test results when coordinating multimodal prostate cancer care. |
| 207Q00000X | Hematology & Oncology | Specialists involved in cancer diagnostics and systemic therapy coordination. |
| 363LA2200X | Clinical Laboratory | Laboratory directors and molecular pathology labs perform or oversee the PLA testing workflow. |
| 207K00000X | Urology | Urologists managing prostate cancer may order the test pre-radiation and counsel patients on risks. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
| Data not available in the input. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0534U | PROSTOX™ ultra (MiraDx Inc.) — 32-variant RT–PCR assay generating a risk score for genitourinary toxicity after radiation | Primary PLA code for this proprietary test; reports results used in radiation treatment planning. |
88172 | Flow cytometry interpretation (example of molecular test adjunct) | May be performed in molecular labs for ancillary cellular analyses; not routine for this assay but listed as an example of laboratory adjunct services. |
88360 | Morphometric analysis; computer-assisted | May be used in pathology workflows for quantitative analysis when tissue-based correlates are evaluated alongside molecular testing. |
81479 | Unlisted molecular pathology procedure | May be used for reporting additional molecular analyses not covered by a specific PLA when clinically indicated. |
99000 | Handling and/or conveyance of specimen | May be used for additional specimen handling fees in certain institutional billing models. |